These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9192926)

  • 41. Pulse nebulization in pneumatic devices.
    Gradoń L; Sosnowski TR; Podolec Z
    Int J Occup Saf Ergon; 1999; 5(1):31-42. PubMed ID: 10602637
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aerosolized dornase alfa in cystic fibrosis: is there a role in the management of patients with early obstructive lung disease?
    Geller DE
    Pediatr Pulmonol; 1997 Aug; 24(2):155-8; discussion 159-61. PubMed ID: 9292913
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Airway inflammation after treatment with aerosolized deoxyribonuclease in cystic fibrosis.
    Henry RL; Gibson PG; Carty K; Cai Y; Francis JL
    Pediatr Pulmonol; 1998 Aug; 26(2):97-100. PubMed ID: 9727759
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nebulization of PEGylated recombinant human deoxyribonuclease I using vibrating membrane nebulizers: A technical feasibility study.
    Mahri S; Wilms T; Hagedorm P; Guichard MJ; Vanvarenberg K; Dumoulin M; Frijlink H; Vanbever R
    Eur J Pharm Sci; 2023 Oct; 189():106522. PubMed ID: 37423579
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of administration of aerosolized recombinant human deoxyribonuclease on resting energy expenditure in patients with cystic fibrosis.
    Amin N; Dozor AJ
    Pediatr Pulmonol; 1994 Sep; 18(3):150-4. PubMed ID: 7800431
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis.
    Shah PL; Scott SF; Knight RA; Marriott C; Ranasinha C; Hodson ME
    Thorax; 1996 Feb; 51(2):119-25. PubMed ID: 8711640
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro aerodynamic characterization of the dose emitted during nebulization of tobramycin high strength solution by novel and jet nebulizer delivery systems.
    Mashat M; Clark BJ; Assi KH; Chrystyn H
    Pulm Pharmacol Ther; 2016 Apr; 37():37-42. PubMed ID: 26747025
    [TBL] [Abstract][Full Text] [Related]  

  • 48. RhDNase before airway clearance therapy improves airway patency in children with CF.
    van der Giessen LJ; de Jongste JC; Gosselink R; Hop WC; Tiddens HA
    Pediatr Pulmonol; 2007 Jul; 42(7):624-30. PubMed ID: 17534979
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New treatment strategies in cystic fibrosis: rhDNase.
    Shah PL; Hodson ME
    Monaldi Arch Chest Dis; 1996 Apr; 51(2):125-9. PubMed ID: 8680379
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Socioeconomic evaluation of the effect of rhDNase on the cost of treating infections of the respiratory tract in patients with cystic fibrosis].
    von der Schulenburg JM; Greiner W; von der Hardt H
    Med Klin (Munich); 1995 Apr; 90(4):220-4. PubMed ID: 7776934
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Statistical analysis of the long-term effects of recombinant human deoxyribonuclease on pulmonary function in cystic fibrosis patients.
    Chen JJ; Hamilton SA
    J Biopharm Stat; 2000 Aug; 10(3):287-97. PubMed ID: 10959912
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Retrospective review of the effects of rhDNase in children with cystic fibrosis.
    Davies J; Trindade MT; Wallis C; Rosenthal M; Crawford O; Bush A
    Pediatr Pulmonol; 1997 Apr; 23(4):243-8. PubMed ID: 9141109
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aerosolization of tobramycin (TOBI) with the PARI LC PLUS reusable nebulizer: which compressor to use? Comparison of the CR60 to the PortaNeb compressor.
    Westerman EM; Boer AH; Touw DJ; Brun PP; Roldaan AC; Frijlink HW; Heijerman HG
    J Aerosol Med Pulm Drug Deliv; 2008 Sep; 21(3):269-80. PubMed ID: 18759658
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [New pharmacological approaches: rhDNase].
    Tournier G; Sardet A; Grosskopf C; Baculard A; Delaisi B
    Rev Pneumol Clin; 1995; 51(3):193-200. PubMed ID: 7569583
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis.
    Suri R; Wallis C; Bush A; Thompson S; Normand C; Flather M; Grieve R; Metcalfe C; Lees B
    Health Technol Assess; 2002; 6(34):iii, 1-60. PubMed ID: 12583821
    [No Abstract]   [Full Text] [Related]  

  • 56. Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.
    Eisenberg JD; Aitken ML; Dorkin HL; Harwood IR; Ramsey BW; Schidlow DV; Wilmott RW; Wohl ME; Fuchs HJ; Christiansen DH; Smith AL
    J Pediatr; 1997 Jul; 131(1 Pt 1):118-24. PubMed ID: 9255202
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial.
    Suri R; Metcalfe C; Lees B; Grieve R; Flather M; Normand C; Thompson S; Bush A; Wallis C
    Lancet; 2001 Oct; 358(9290):1316-21. PubMed ID: 11684212
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis.
    Robinson TE; Goris ML; Zhu HJ; Chen X; Bhise P; Sheikh F; Moss RB
    Chest; 2005 Oct; 128(4):2327-35. PubMed ID: 16236891
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients.
    Sawicki GS; Chou W; Raimundo K; Trzaskoma B; Konstan MW
    J Cyst Fibros; 2015 Nov; 14(6):777-83. PubMed ID: 25921451
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nebulizer choice for inhaled colistin treatment in cystic fibrosis.
    Katz SL; Ho SL; Coates AL
    Chest; 2001 Jan; 119(1):250-5. PubMed ID: 11157612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.